These data suggested that CDK1 and iASPP was correlated with poorer CRC prognosis, respectively; targeting CDK1 and iASPP to inhibit their expression, thus to rescue the expression of p53 pathway-related factors showed to be a promising strategy in CRC treatment. This evidence concerns the gene CDK1 and colorectal carcinoma.